ReviewFrontiers in immunology2026
Case Report: Overlap syndrome of anti-NMDA receptor encephalitis and MOG-associated disease in a pediatric patient-literature insights.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Anti-NMDA-receptor encephalitis and MOGAD associated optic neuritis: a case series.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) and anti-N-methyl-D- aspartate receptor (NMDAR) encephalitis pediatric cases are especially challenging due to phenotypic variability, limited literature, and the absence of standardized treatment protocols. We present the first documented African case of pediatric MOG and NMDAR overlapping syndrome (MNOS), with a review of all pediatric MNOS cases reported thus far in the literature. A previously healthy seven-year-old boy developed rapid-onset sleep disturbances, neuropsychiatric symptoms, multiple cranial nerve palsies, and hyperkinetic movements. Serological and cerebrospinal fluid (CSF) analyses confirmed dual positivity for anti- MOG and anti- NMDAR antibodies. The patient responded favorably to first line immunotherapy with intravenous immunoglobulin and corticosteroids, showing marked clinical improvement by the six-month follow-up. A corticosteroid taper was initiated thereafter. At fourteen-month follow-up, he had a second episode with a MOGAD- associated cerebral cortical encephalitis phenotype. Antibody screening confirmed persistent dual positivity for both anti-NMDAR and anti-MOG antibodies. The clinical outcome was favorable following first-line immunotherapy combined with oral immunosuppressants. This case highlights the uniqueness of this entity, where antibody dynamics are closely tied to the clinical course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.